Search trials – HealthDB

Активни:

Намерени 3,079 изпитвания Стр. 4 от 154

By invitation only Phase 3

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

This is a 2-year open-label, multicenter extension of the double-blind, placebo-controlled GTi1201 study. The purpose of this study is to obtain an additional 2 years of safety data for intravenously administered Alpha1-MP 60 mg/kg/week in subjects with alpha1-antitrypsin deficiency (AATD).

Начало: 01.07.2016 Край: 01.02.2029 Възраст: 20–72 г. Treatment

Australia, Canada, Denmark +9 Grifols Therapeutics LLC NCT02796937

By invitation only

A Clinical Registry of Orthobiologics Procedures

Orthopedic Disorder

The purpose of the Registry study is to observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures for treatment of musculoskeletal disorders.

Начало: 01.02.2016 Край: 01.02.2036

Australia, India, United States Regenexx, LLC NCT03011398

By invitation only

Registry of Patients With Hypophosphatasia

Hypophosphatasia (HPP)

In this prospective, observational, long term registry patients of all ages with a diagnosis of hypophosphatasia (HPP) are followed at participating sites in multiple countries.

Начало: 20.01.2015 Край: 31.12.2031

Australia, Canada, France +7 Alexion Pharmaceuticals, Inc. NCT02306720

By invitation only

Multicenter Assessment of the Pancreas in Type 1 Diabetes

Diabetes Mellitus

The overall goal of this research is to develop and validate standard operating procedures (SOP) to assess the human pancreas in individuals with type 1 diabetes (T1D) and other forms of diabetes using advanced, quantitative magnetic resonance imaging (MRI) approaches.

Начало: 19.02.2014 Край: 01.12.2050 Възраст: от 8 г.

Australia, United States Vanderbilt University Medical Center NCT03585153

By invitation only

Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease

Legg Calve Perthes Disease

Legg-Calvé-Perthes disease is a childhood hip disorder which is common enough to be a significant public health problem (affects 1 in 740 boys between ages 0-14), but uncommon enough to have a sufficient number of patients from a single institution to perform a definitive prospective study comparing the results of current treatments. The present study will establish a database of prospectively identified patients with Legg-Calvé-Perthes (LCP) Disease and collect information regarding their presentation, treatment, and outcomes in the course of receiving currently available treatments. This study seeks to compare the outcomes of current treatments in the management of different age groups (ages 1-6, 6-8, 8-11, \>11) of patients with Perthes disease at two- and five-year followup and at skeletal maturity. For each age group, two to three common treatment regimens currently used by practicing pediatric orthopaedic surgeons will be compared. The intervention a patient receives is determined through physician treatment expertise, and is not pre-determined by the study.

Начало: 01.08.2012 Край: 01.09.2032 Възраст: 1–18 г.

Australia, Brazil, Canada +11 Texas Scottish Rite Hospital for Children NCT02040714

Approved for marketing

EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Neoplasms, Breast

This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies

Начало: 01.07.2006 Край: 01.03.2015 Възраст: от 18 г.

Australia, Belgium, Brazil +36 Novartis NCT00338247

Approved for marketing

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

Начало: 01.07.2005 Край: 01.11.2011 Възраст: от 18 г.

Argentina, Australia, Belgium +43 Pfizer NCT00130897

Approved for marketing

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Gastrointestinal Neoplasm

The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248.

Начало: 01.09.2004 Край: 01.10.2011 Възраст: от 18 г.

Argentina, Australia, Belgium +28 Pfizer NCT00094029

Approved for marketing

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

HIV Infections

To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.

Начало: 01.05.2003 Край: 01.04.2014 Възраст: от 2 г.

Australia, Belgium, Denmark +9 Boehringer Ingelheim NCT00062660

Available

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Non Small Cell Lung Cancer ALK-positive Non-small Cell Lung Cancer (NSCLC)

The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.

Възраст: от 18 г.

Australia, Canada, France +9 Nuvalent Inc. NCT06834074

Available

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Hunter Syndrome

As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.

Australia, Mexico, Spain +2 Takeda NCT05795361

Approved for marketing

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer +3

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Възраст: от 18 г.

Australia, France, Germany +10 Eli Lilly and Company NCT03906331

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.

Възраст: 18–130 г.

Argentina, Australia, Brazil +15 AstraZeneca NCT00683306

Available

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

Non Small Cell Lung Cancer ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.

Възраст: от 18 г.

Australia, Canada, France +7 Nuvalent Inc. NCT06797362

Approved for marketing

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

SARS-CoV2 Infection

The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.

Възраст: от 12 г.

Australia, Belgium, Canada +20 Gilead Sciences NCT04323761

Approved for marketing

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Carcinoma, Non-Small-Cell Lung

The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib. The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use. Named Patient Use (NPU)

Възраст: от 18 г.

Australia Boehringer Ingelheim NCT01209650

Approved for marketing

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Възраст: от 18 г.

Australia, Canada, Egypt +11 Eli Lilly and Company NCT03763604

Approved for marketing

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Prostate Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male

The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).

Възраст: 18–99 г.

Australia, Brazil, Canada +21 Johnson & Johnson Pharmaceutical Research & Development NCT01217697

Approved for marketing

Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

Major Depressive Disorder Fibromyalgia Diabetic Peripheral Neuropathic Pain Generalized Anxiety Disorder

The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.

Възраст: от 18 г.

Australia Eli Lilly and Company NCT00071708

Available

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Dravet Syndrome Lennox Gastaut Syndrome Developmental and Epileptic Encephalopathies

This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs. The EAP study will allow continued treatment with LP352 for eligible participants diagnosed with treatment resistant DEEs who successfully completed an LP352 Clinical Trial (Enrollment by Invitation) or an immediate family member who has the exact same gene mutation resulting in the same DEE epilepsy syndrome phenotype or a patient who previously participated in the lorcaserin EAP.

Възраст: 2–65 г.

Australia, United States Longboard Pharmaceuticals NCT06149663

1 2 3 4 5 6 … 154